Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma

Journal of Hepatology

Volumn 65, Issue 4, 2016, Pages 859-860

  Yang, Ju Dong ^a   Aqel, Bashar A ^b   Pungpapong, Surakit ^c   Gores, Gregory J ^a   Roberts, Lewis R ^a   Leise, Michael D ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CHEMOEMBOLIZATION; DISEASE ASSOCIATION; HEPATITIS C; HIGH RISK PATIENT; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RADIOFREQUENCY ABLATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; VIRAL CLEARANCE; CHRONIC HEPATITIS C; LIVER TUMOR; RECURRENT DISEASE; TUMOR RECURRENCE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; RECURRENCE;

EID: 84979753518     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.06.023     Document Type: Letter

References (8)

1. [1] Reig, M., Marino, Z., Perello, C., et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 65 (2016), 719–726.
2. [2] Cammà, C., Cabibbo, G., Craxì, A., Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol 65 (2016), 861–862.
3. [3] Buonfiglioli F, Conti F, Andreone P, Crespi C, Foschi FG, Lenzi M, et al. Development of Hepatocellular Carcinoma in HCV cirrhotic patients treated with direct acting antivirals, Abstracts of The International Liver Congress(TM) 2016–51th Annual meeting of the European Association for the Study of the Liver.
4. [4] Pol, S., Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts). J Hepatol 65 (2016), 734–740.
5. [5] Pawlotsky, J.M., Feld, J.J., Zeuzem, S., et al. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol 62 (2015), S87–S99.
6. [6] Hsu, Y.C., Ho, H.J., Wu, M.S., et al. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology 58 (2013), 150–157.
7. [7] Curry, M.P., Forns, X., Chung, R.T., et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148 (2015), 100–107, e1.
8. [8] Yang JD, Aqel BA, Watt KD, Vargas HE, Keaveny AP, Pungpapong S, et al. Hepatitis C and HCC outcomes among patients listed for liver transplant with HCV-HCC who received direct acting antiviral therapy. The Liver Meeting 2015-AASLD.